176 related articles for article (PubMed ID: 35264027)
21. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
[TBL] [Abstract][Full Text] [Related]
22. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort.
Adland E; Jesuthasan G; Downs L; Wharton V; Wilde G; McNaughton AL; Collier J; Barnes E; Klenerman P; Andersson M; Jeffery K; Matthews PC
BMC Infect Dis; 2018 Sep; 18(1):461. PubMed ID: 30217169
[TBL] [Abstract][Full Text] [Related]
25. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
[TBL] [Abstract][Full Text] [Related]
26. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
27. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
[TBL] [Abstract][Full Text] [Related]
28. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
29. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
32. Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
Wolfson-Stofko B; Hirode G; Vanderhoff A; Karkada J; Capraru C; Biondi MJ; Hansen B; Shah H; Janssen HLA; Feld JJ
J Viral Hepat; 2024 May; 31(5):240-247. PubMed ID: 38385850
[TBL] [Abstract][Full Text] [Related]
33. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set.
Morgan JR; Marsh E; Savinkina A; Shilton S; Shadaker S; Tsertsvadze T; Kamkamidze G; Alkhazashvili M; Morgan T; Belperio P; Backus L; Doss W; Esmat G; Hassany M; Elsharkawy A; Elakel W; Mehrez M; Foster GR; Wose Kinge C; Chew KW; Chasela CS; Sanne IM; Thanung YM; Loarec A; Aslam K; Balkan S; Easterbrook PJ; Linas BP
J Viral Hepat; 2022 Jun; 29(6):474-486. PubMed ID: 35278339
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Amele S; Peters L; Rodger A; Lundgren J; Rockstroh J; Matulionyte R; Leen C; Jabłonowska E; Østergaard L; Bhagani S; Sarcletti M; Clarke A; Falconer K; Wandeler G; Domingo P; Maltez F; Zaccarelli M; Chkhartisvili N; Szlavik J; Stephan C; Fonquernie L; Aho I; Mocroft A;
J Acquir Immune Defic Syndr; 2021 Feb; 86(2):248-257. PubMed ID: 33079903
[TBL] [Abstract][Full Text] [Related]
35. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
[TBL] [Abstract][Full Text] [Related]
36. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
[TBL] [Abstract][Full Text] [Related]
37. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
38. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
39. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma.
Kamp WM; Sellers CM; Stein S; Lim JK; Kim HS
J Vasc Interv Radiol; 2020 Jun; 31(6):953-960. PubMed ID: 32376182
[TBL] [Abstract][Full Text] [Related]
40. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.
Seaman A; King CA; Kaser T; Geduldig A; Ronan W; Cook R; Chan B; Levander XA; Priest KC; Korthuis PT
Int J Drug Policy; 2021 Oct; 96():103359. PubMed ID: 34325969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]